The antidepressant duloxetine does not appear to prevent chemotherapy-associated nerve damage in colorectal cancer. This finding appeared in the JCO Oncology Advances on March 25, 2026 followed by… read more.
NICE(UK): Belantamab mafodotin plus pomalidomide and dexamethasone can be used as an option to treat multiple myeloma in adults, if: i) they have only had 1 line of treatment… read more.
The FDA approved Boehringer Ingelheim’s Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase… read more.
Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are presented today… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a certain type of breast… read more.
The company’s partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziiher (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being… read more.
Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in grit and resilience between the… read more.
The company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending the granting of a marketing authorisation for Poherdy in combination with trastuzumab and… read more.
Pfizer Inc. announced the FDA has granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux ) and fluorouracil-based chemotherapy for the treatment of adult patients with… read more.
Despite recent advancements in breast cancer treatments, new breast cancer cases in women are predicted to rise by a third globally from 2.3 million in 2023 to more than 3.5 million in 2050. Similarly, yearly deaths… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to Jazz Pharmaceuticals Research UK Limited for zanidatamab (Ziihera) in adults to treat biliary tract cancer whose cancer… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
